Search

Your search keyword '"P. S. Shilo"' showing total 3 results
Start Over Author "P. S. Shilo" Search Limiters Full Text
3 results on '"P. S. Shilo"'

1. CLINICAL, LABORATORY AND X-RAY PECULIARITIES OF INVASIVE ASPERGILLOSIS IN B-CELLULAR LYMPHOMS PATIENTS

Author

Y. A. CHUDINOVSKIKH, T. Y. SEMIGLAZOVA, N. N. KLIMKO, A. A. BARCHUK, O. V. SHADRIVOVA, E. V. FROLOVA, T. S. BOGOMOLOVA, S. M. IGNATIEVA, S. M. ALEXEEV, I. S. ZYUZGIN, L. V. FILATOVA, V. V. SEMIGLAZOV, E. V. KHARCHENKO, A. B. KOSICHKINA, M. S. MOTALKINA, U. B. KHADONOV, Y. A. OLEYNIK, A. A. ZVERKOVA, I. V. OSHMATOVA, A. Y. SUBORA, S. A. SHALAEV, and P. S. SHILO

Subjects
invasive aspergillosis, b-cell lymphoma, aspergillus spp, Medicine
Abstract

The study included 108 patients with B-cell lymphoma which had complication with invasive aspergillosis, 57 patients with Hodgkin lymphoma (HL) and 51 patients with non-Hodgkin lymphoma (NHL). All patients in both groups received chemotherapy before the development of invasive aspergillosis, 73% of patients with HL and 67% patients with NHL received chemotherapy for induction and consolidation of remission. The main predictive factors for IA in patients with HL and NHL were: prolonged lymphocytopenia (70% vs 48%), agranulocytosis (64% vs 71%), use of glucocorticosteroids as part of treatment protocol (61% vs 85%), presence of B – symptoms (63% vs 48%), respectively. In most cases nosocomial invasive aspergillosis was diagnosed in both groups: 65% vs 83% respectively. We identified etiological agents in Hodgkin and non-Hodgkin lymphoma patients: A. fumigatus (50% vs 39%), A. niger (43% vs 33%) and A. flavus (7% vs 8%). The lungs were involved in 100% cases, in group with NHL patients 6% had combined lesions in lungs and other organs and different types of tissues. Clinical manifestation of IA was nonspecific in both groups: fever – 83% vs 76%, cough – 75% vs 59%, respiratory insufficiency – 50% vs 40%, respectively. CT-signs of IA were also nonspecific in both groups: infiltrative (75% vs 66%), focal changes (61% vs 63%), and «ground-glass opacity» (28% vs 31%), respectively. In most cases patients were treated with voriconazole in both patients (88% vs 98%). Overall 12-weeks survival in patients with Hodgkin lymphoma and invasive aspergillosis was 84%, in patients with non-Hodgkin lymphoma and invasive aspergillosis – 81%.

Published
2017
Full Text
View/download PDF

2. DIFFERENTIAL DIAGNOSIS OF LYMPHOMAS OF THE MEDIASTINUM: A VIEW OF THE ONCOLOGIST AND PATHOLOGIST

Author

E. V. KHARCHENKO, A. S. ARTEMYEVA, T. Y. SEMIGLAZOVA, V. F. KLIMASHEVSKY, S. M. ALEXEEV, I. S. ZYUZGIN, L. V. FILATOVA, M. S. MOTALKINA, V. V. SEMIGLAZOV, Y. A. CHUDINOVSKY, D. A. ZVYAGINTSEVA, U. B. KHADONOV, P. S. SHILO, V. A. KUSHNAREV, and A. B. KOSICHKINA

Subjects
mediastinal lymphoma, hodgkin lymphoma, b-cell lymphoma, т-cell lymphoma, differential diagnosis, Medicine
Abstract

The clinic-rentgenological differential diagnosis is difficult especially in case of localized mediastinal disease. Just detailed histological diagnosis allows making a right tactic decision and choosing effective therapy. Furthermore, some indolent B-cell lymphomas and T-cell lymphomas can arise in mediastinum. Mediastinal tumors are frequent in young adults, and most of these neoplasms are lymphoproliferative disorders. The spectrum of mediastinal lymphoma is broad. The most often of them are large B-cell lymphomas: classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, diffuse large B-cell lymphoma and mediastinal grey zone lymphoma.

Published
2017
Full Text
View/download PDF

3. Personalized therapy in solid tumors: results of a retrospective multicentre study of the clinical applicability of the FoundationOne® Medicine Test

Author

M. L. Stepanova, O. A. Kuznetsovа, P. S. Shilo, F. V. Moiseenko, N. Kh. Abduloeva, E. V. Artemyeva, A. S. Zhabina, M. M. Kramchaninov, N. M. Volkov, I. A. Pokataev, A. A. Rumyantsev, I. L. Plaksa, M. A. Gairyan, A. A. Isaev, M. V. Ivanov, Yu. F. Sadykova, V. A. Mileiko, V. V. Shamrikova, E. V. Ledin, A. A. Tryakin, and M. Yu. Fedyanin

Subjects
General Medicine
Abstract

Background. The use of targeted sequencing panels makes it possible to optimize and personalize the treatment strategy for cancer patients. Given the lack of a clear «portrait of the patient», the role of large panels (200 or more genes) in the treatment of a patient has not yet been determined.Aim. Assessment of the relationship between the results of targeted sequencing of tumor tissue or ctDNA and the treatment carried out after obtaining these data in patients with various solid tumors.Materials and methods. We retrospectively evaluated the NGS results and the treatments, provided to the 184 patients after NGS testing between 06.2016 and 06.2021. For analysis, one of two methods is used: a histological sample or the patient’s blood plasma. Evaluation of the results and determination of treatment tactics were carried out within the framework of a multidisciplinary commission. The frequency of detection of molecular disorders, the number of mutations in each sample, and the frequency of detection of targets for targeted therapy were assessed.Results. Molecular disorders were detected in 88.5 % (n = 163). The average number of mutations in one sample was 6. The maximum was detected in colorectal cancer patients; their average value was 8. The minimum was determined in non-small cell lung cancer and ovarian cancer patients, the average number of mutations was 3 in each localization. The average time from the moment the material was received by the laboratory to the generation of the report was 11 days. Targeted targets were identified in 25 (13.6 %) patients and therapy was started. Therapy with tyrosine kinase inhibitors of the first – third generations were performed in 12 (48 %) patients, PARP inhibitors – in 3 (24 %), BRAF and MEK inhibitors – in 2 (8 %), anti-HER2 therapy – in 1 (4 %). Targeted therapy within international clinical trials was initiated in 4 (16 %) patients. Immunotherapy was recommended in 3 (12 %) patients. In multivariate analysis, the chance of prescribing therapy based on the results of FM1 analysis was influenced by: mRAS (odds ratio 0.08; 95 % confidence interval 0.01–0.65; p = 0.018) and mEGFR (odds ratio 4.8; 95 % confidence interval 1.4–16.3; p = 0.012).Conclusion. The effectiveness of the FM1 test in real clinical practice in the Russian Federation corresponds to international data. In the presence of a mutation in the RAS genes, an additional FM1 test determines a low chance of detecting clinically significant disorders for which personalized treatment can be prescribed. The high frequency of prescription of therapy based on the results of blood plasma tests is due to the cohort of patients with non-small cell lung cancer and the detection of a mutation in the EGFR gene.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results